|
G |
G6PD |
glucose-6-phosphate dehydrogenase |
increases activity |
EXP |
Methylphenazonium Methosulfate results in increased activity of G6PD protein |
CTD |
PMID:1901343 |
|
NCBI chr X:154,531,390...154,547,569
Ensembl chr X:154,517,825...154,547,572
|
|
G |
PGD |
phosphogluconate dehydrogenase |
increases activity |
EXP |
Methylphenazonium Methosulfate results in increased activity of PGD protein |
CTD |
PMID:1901343 |
|
NCBI chr 1:10,399,064...10,420,511
Ensembl chr 1:10,398,592...10,420,511
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases transport multiple interactions |
EXP |
ABCB1 protein results in increased transport of Atazanavir Sulfate [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:29859254 PMID:33819548 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
EXP |
Atazanavir Sulfate results in decreased activity of ABCB11 protein Atazanavir Sulfate inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:24014644 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCB4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:87,365,896...87,476,027
Ensembl chr 7:87,401,696...87,480,435
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
EXP |
Atazanavir Sulfate results in decreased expression of ABCC2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr10:99,782,640...99,852,594
Ensembl chr10:99,782,640...99,852,594
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
decreases expression |
EXP |
Atazanavir Sulfate results in decreased expression of ABCC3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCG2 |
ATP binding cassette subfamily G member 2 (JR blood group) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:88,090,264...88,231,626
Ensembl chr 4:88,090,150...88,231,628
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACSL1 |
acyl-CoA synthetase long chain family member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
|
|
G |
ADGRG1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:57,619,738...57,665,567
Ensembl chr16:57,610,652...57,665,580
|
|
G |
ADH1C |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,336,497...99,352,746
Ensembl chr 4:99,336,497...99,352,746
|
|
G |
ADH4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,123,658...99,144,297
Ensembl chr 4:99,123,657...99,157,792
|
|
G |
ADH6 |
alcohol dehydrogenase 6 (class V) |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,202,639...99,219,246
Ensembl chr 4:99,202,638...99,219,537
|
|
G |
AKR1C4 |
aldo-keto reductase family 1 member C4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1C4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:5,196,837...5,218,949
Ensembl chr10:5,195,462...5,218,949
|
|
G |
AKR1D1 |
aldo-keto reductase family 1 member D1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:138,076,459...138,118,305
Ensembl chr 7:138,002,324...138,118,305
|
|
G |
AKR7A3 |
aldo-keto reductase family 7 member A3 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of AKR7A3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:19,274,229...19,288,770
Ensembl chr 1:19,282,573...19,288,770
|
|
G |
ALB |
albumin |
affects binding multiple interactions |
EXP |
Atazanavir Sulfate binds to ALB protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA |
CTD |
PMID:15814459 PMID:16336266 PMID:33819548 |
|
NCBI chr 4:73,404,287...73,421,482
Ensembl chr 4:73,397,114...73,421,482
|
|
G |
ALPP |
alkaline phosphatase, placental |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:232,378,751...232,382,889
Ensembl chr 2:232,378,724...232,382,889
|
|
G |
AMPD3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:10,450,388...10,507,579
Ensembl chr11:10,308,313...10,507,579
|
|
G |
APOA1 |
apolipoprotein A1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:116,835,751...116,837,622
Ensembl chr11:116,835,751...116,837,622
|
|
G |
ATF4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA Atazanavir Sulfate results in increased expression of ATF4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr22:39,520,559...39,522,686
Ensembl chr22:39,519,695...39,522,686
|
|
G |
ATF6 |
activating transcription factor 6 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA Atazanavir Sulfate results in increased expression of ATF6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:161,766,320...161,964,070
Ensembl chr 1:161,766,298...161,977,574
|
|
G |
ATG7 |
autophagy related 7 |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of ATG7 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:11,272,397...11,576,353
Ensembl chr 3:11,272,309...11,557,665
|
|
G |
ATP8B1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:57,646,426...57,803,315
Ensembl chr18:57,646,426...57,803,315
|
|
G |
BAAT |
bile acid-CoA:amino acid N-acyltransferase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:101,360,417...101,385,006
Ensembl chr 9:101,354,182...101,385,400
|
|
G |
BCL2L1 |
BCL2 like 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:31,664,452...31,723,963
Ensembl chr20:31,664,452...31,723,989
|
|
G |
CAT |
catalase |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA Atazanavir Sulfate results in decreased expression of CAT mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCL2 |
C-C motif chemokine ligand 2 |
increases expression |
EXP |
Atazanavir Sulfate results in increased expression of CCL2 protein |
CTD |
PMID:17668557 |
|
NCBI chr17:34,255,285...34,257,203
Ensembl chr17:34,255,274...34,257,208
|
|
G |
CCL3 |
C-C motif chemokine ligand 3 |
increases expression |
EXP |
Atazanavir Sulfate results in increased expression of CCL3 protein |
CTD |
PMID:17668557 |
|
NCBI chr17:36,088,256...36,090,143
Ensembl chr17:36,088,256...36,090,169
|
|
G |
CHI3L1 |
chitinase 3 like 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:203,178,931...203,186,704
Ensembl chr 1:203,178,931...203,186,704
|
|
G |
CSF1 |
colony stimulating factor 1 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA Atazanavir Sulfate results in increased expression of CSF1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:109,910,506...109,930,992
Ensembl chr 1:109,910,242...109,930,992
|
|
G |
CTNNB1 |
catenin beta 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:41,199,505...41,240,443
Ensembl chr 3:41,194,741...41,260,096
|
|
G |
CTTN |
cortactin |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:70,398,529...70,436,575
Ensembl chr11:70,398,404...70,436,584
|
|
G |
CXCL8 |
C-X-C motif chemokine ligand 8 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CXCL8 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:73,740,569...73,743,716
Ensembl chr 4:73,740,519...73,743,716
|
|
G |
CYLD |
CYLD lysine 63 deubiquitinase |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA Atazanavir Sulfate results in increased expression of CYLD mRNA |
CTD |
PMID:32152650 |
|
NCBI chr16:50,742,086...50,801,935
Ensembl chr16:50,742,050...50,801,935
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:74,748,845...74,756,607
Ensembl chr15:74,748,845...74,756,607
|
|
G |
CYP27A1 |
cytochrome P450 family 27 subfamily A member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:218,782,147...218,815,293
Ensembl chr 2:218,781,749...218,815,293
|
|
G |
CYP2A6 |
cytochrome P450 family 2 subfamily A member 6 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2A6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:40,843,541...40,850,447
Ensembl chr19:40,843,541...40,850,447
|
|
G |
CYP2B6 |
cytochrome P450 family 2 subfamily B member 6 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of CYP2B6 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:40,991,282...41,018,398
Ensembl chr19:40,991,282...41,018,398
|
|
G |
CYP2C18 |
cytochrome P450 family 2 subfamily C member 18 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:94,683,729...94,736,190
Ensembl chr10:94,683,729...94,736,190
|
|
G |
CYP2C19 |
cytochrome P450 family 2 subfamily C member 19 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:94,762,681...94,855,547
Ensembl chr10:94,762,681...94,855,547
|
|
G |
CYP2C9 |
cytochrome P450 family 2 subfamily C member 9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:94,938,658...94,990,091
Ensembl chr10:94,938,658...94,990,091
|
|
G |
CYP3A4 |
cytochrome P450 family 3 subfamily A member 4 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA Atazanavir Sulfate results in decreased expression of CYP3A4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:99,756,967...99,784,184
Ensembl chr 7:99,756,960...99,784,248
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP7A1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA Atazanavir Sulfate results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:58,490,178...58,500,163
Ensembl chr 8:58,490,178...58,500,163
|
|
G |
CYP7B1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:64,586,575...64,798,737
Ensembl chr 8:64,587,763...64,798,737
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of DDIT3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DNAJB9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:108,569,874...108,574,850
Ensembl chr 7:108,569,867...108,574,850
|
|
G |
DNAJC10 |
DnaJ heat shock protein family (Hsp40) member C10 |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of DNAJC10 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:182,716,257...182,794,464
Ensembl chr 2:182,716,255...182,794,464
|
|
G |
DNAJC12 |
DnaJ heat shock protein family (Hsp40) member C12 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:67,796,669...67,838,188
Ensembl chr10:67,796,669...67,838,188
|
|
G |
DNAJC9 |
DnaJ heat shock protein family (Hsp40) member C9 |
increases expression |
EXP |
Atazanavir Sulfate results in increased expression of DNAJC9 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr10:73,232,272...73,247,255
Ensembl chr10:73,183,362...73,247,255
|
|
G |
EPHX1 |
epoxide hydrolase 1 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA Atazanavir Sulfate results in decreased expression of EPHX1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:225,810,124...225,845,563
Ensembl chr 1:225,810,124...225,845,563
|
|
G |
FKBP5 |
FKBP prolyl isomerase 5 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA Atazanavir Sulfate results in decreased expression of FKBP5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:35,573,590...35,728,583
Ensembl chr 6:35,573,585...35,728,583
|
|
G |
FMO1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
EXP |
Atazanavir Sulfate results in decreased expression of FMO1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
|
|
G |
FOSL1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of FOSL1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:65,892,049...65,900,545
Ensembl chr11:65,892,049...65,900,573
|
|
G |
GGT1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr22:24,583,750...24,628,996
Ensembl chr22:24,594,811...24,629,005
|
|
G |
GJB1 |
gap junction protein beta 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:71,215,239...71,225,516
Ensembl chr X:71,212,811...71,225,516
|
|
G |
GK |
glycerol kinase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:30,653,423...30,731,462
Ensembl chr X:30,653,359...30,731,462
|
|
G |
GPRC5B |
G protein-coupled receptor class C group 5 member B |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:19,856,691...19,885,634
Ensembl chr16:19,856,691...19,886,167
|
|
G |
GPX2 |
glutathione peroxidase 2 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of GPX2 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GSTA1 |
glutathione S-transferase alpha 1 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA Atazanavir Sulfate results in decreased expression of GSTA1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:52,791,371...52,803,816
Ensembl chr 6:52,791,371...52,803,860
|
|
G |
GSTA3 |
glutathione S-transferase alpha 3 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of GSTA3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:52,896,646...52,909,698
Ensembl chr 6:52,896,639...52,909,698
|
|
G |
GSTM4 |
glutathione S-transferase mu 4 |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:109,656,099...109,667,727
Ensembl chr 1:109,656,099...109,665,496
|
|
G |
HACL1 |
2-hydroxyacyl-CoA lyase 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:15,560,699...15,601,569
Ensembl chr 3:15,560,699...15,601,852
|
|
G |
HGF |
hepatocyte growth factor |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:81,699,010...81,770,047
Ensembl chr 7:81,699,010...81,770,438
|
|
G |
HMOX1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of HMOX1 mRNA; Atazanavir Sulfate results in increased expression of HMOX1 protein Atazanavir Sulfate promotes the reaction [HMOX1 protein results in increased chemical synthesis of Bilirubin]; Ritonavir promotes the reaction [Atazanavir Sulfate results in increased expression of HMOX1 mRNA] |
CTD |
PMID:26968795 |
|
NCBI chr22:35,381,096...35,394,207
Ensembl chr22:35,380,361...35,394,214
|
|
G |
HPX |
hemopexin |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:6,431,049...6,440,987
Ensembl chr11:6,431,049...6,442,617
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA Atazanavir Sulfate results in decreased expression of HSPA5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 9:125,234,853...125,241,343
Ensembl chr 9:125,234,853...125,241,382
|
|
G |
ICAM1 |
intercellular adhesion molecule 1 |
increases expression |
EXP |
Atazanavir Sulfate results in increased expression of ICAM1 protein |
CTD |
PMID:26968795 |
|
NCBI chr19:10,271,120...10,286,615
Ensembl chr19:10,271,093...10,286,615
|
|
G |
IER3 |
immediate early response 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:30,743,199...30,744,547
Ensembl chr 6:30,743,199...30,744,548
|
|
G |
IFI16 |
interferon gamma inducible protein 16 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:158,999,976...159,055,151
Ensembl chr 1:158,999,968...159,055,155
|
|
G |
IFI27 |
interferon alpha inducible protein 27 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:94,105,894...94,116,690
Ensembl chr14:94,104,836...94,116,695
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
IL6 |
interleukin 6 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:22,727,200...22,731,998
Ensembl chr 7:22,725,884...22,732,002
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:58,780,791...58,784,047
Ensembl chr 1:58,776,845...58,784,048
|
|
G |
JUND |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:18,279,694...18,281,622
Ensembl chr19:18,279,694...18,281,622
|
|
G |
KYNU |
kynureninase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:142,877,664...143,055,833
Ensembl chr 2:142,877,657...143,055,833
|
|
G |
LBP |
lipopolysaccharide binding protein |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
|
|
G |
LDLR |
low density lipoprotein receptor |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:11,089,463...11,133,820
Ensembl chr19:11,089,418...11,133,820
|
|
G |
LIPC |
lipase C, hepatic type |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
LY96 |
lymphocyte antigen 96 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:73,991,392...74,099,857
Ensembl chr 8:73,991,392...74,029,079
|
|
G |
MAFF |
MAF bZIP transcription factor F |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA Atazanavir Sulfate results in increased expression of MAFF mRNA |
CTD |
PMID:32152650 |
|
NCBI chr22:38,201,994...38,216,511
Ensembl chr22:38,200,767...38,216,507
|
|
G |
MAP1LC3B |
microtubule associated protein 1 light chain 3 beta |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of MAP1LC3B mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:32152650 |
|
NCBI chr16:87,392,336...87,404,774
Ensembl chr16:87,383,953...87,404,779
|
|
G |
MAP2K6 |
mitogen-activated protein kinase kinase 6 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:69,414,697...69,553,865
Ensembl chr17:69,414,697...69,553,865
|
|
G |
MAPKAPK3 |
MAPK activated protein kinase 3 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA Atazanavir Sulfate results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:50,611,520...50,649,291
Ensembl chr 3:50,611,520...50,649,291
|
|
G |
MLKL |
mixed lineage kinase domain like pseudokinase |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of MLKL mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr16:74,671,855...74,700,862
Ensembl chr16:74,671,855...74,700,960
|
|
G |
MMUT |
methylmalonyl-CoA mutase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:49,430,360...49,463,253
Ensembl chr 6:49,430,360...49,463,253
|
|
G |
MTTP |
microsomal triglyceride transfer protein |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:99,564,130...99,623,997
Ensembl chr 4:99,564,081...99,623,997
|
|
G |
NFXL1 |
nuclear transcription factor, X-box binding like 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:47,847,233...47,914,667
Ensembl chr 4:47,847,233...47,914,667
|
|
G |
NR1H3 |
nuclear receptor subfamily 1 group H member 3 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:47,248,300...47,269,033
Ensembl chr11:47,248,300...47,269,033
|
|
G |
NR1H4 |
nuclear receptor subfamily 1 group H member 4 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA Atazanavir Sulfate results in decreased expression of NR1H4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:100,473,866...100,564,414
Ensembl chr12:100,473,708...100,564,414
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of NR1I2 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:119,782,101...119,818,487
Ensembl chr 3:119,780,484...119,818,487
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of NR1I3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:161,229,669...161,238,203
Ensembl chr 1:161,229,666...161,238,244
|
|
G |
PAH |
phenylalanine hydroxylase |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:102,836,889...102,958,441
Ensembl chr12:102,836,889...102,958,410
|
|
G |
PIK3C2G |
phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of PIK3C2G mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:18,242,961...18,726,817
Ensembl chr12:18,242,961...18,648,416
|
|
G |
PIK3R1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA Atazanavir Sulfate results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:68,215,756...68,301,821
Ensembl chr 5:68,215,740...68,301,821
|
|
G |
PON1 |
paraoxonase 1 |
decreases activity |
ISO |
Atazanavir Sulfate results in decreased activity of PON1 protein |
CTD |
PMID:27378623 |
|
NCBI chr 7:95,297,676...95,324,532
Ensembl chr 7:95,297,676...95,324,532
|
|
G |
PPARA |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr22:46,150,526...46,243,756
Ensembl chr22:46,150,521...46,243,755
|
|
G |
PPP1R3C |
protein phosphatase 1 regulatory subunit 3C |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:91,628,442...91,633,071
Ensembl chr10:91,628,442...91,633,071
|
|
G |
RALA |
RAS like proto-oncogene A |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:39,623,572...39,708,120
Ensembl chr 7:39,623,565...39,708,120
|
|
G |
REEP5 |
receptor accessory protein 5 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:112,876,385...112,922,227
Ensembl chr 5:112,876,385...112,922,289
|
|
G |
RIPK1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:3,063,967...3,115,187
Ensembl chr 6:3,063,824...3,115,187
|
|
G |
SCP2 |
sterol carrier protein 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:52,927,276...53,051,698
Ensembl chr 1:52,927,276...53,051,698
|
|
G |
SDC2 |
syndecan 2 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:96,493,813...96,611,790
Ensembl chr 8:96,493,813...96,611,790
|
|
G |
SERPINE1 |
serpin family E member 1 |
increases expression multiple interactions |
EXP |
Atazanavir Sulfate results in increased expression of SERPINE1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:101,127,104...101,139,247
Ensembl chr 7:101,127,104...101,139,247
|
|
G |
SH3GLB1 |
SH3 domain containing GRB2 like, endophilin B1 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA Atazanavir Sulfate results in increased expression of SH3GLB1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:86,704,576...86,748,184
Ensembl chr 1:86,704,570...86,748,184
|
|
G |
SLC10A1 |
solute carrier family 10 member 1 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of SLC10A1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr14:69,775,416...69,797,241
Ensembl chr14:69,775,416...69,797,241
|
|
G |
SLC17A1 |
solute carrier family 17 member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:25,723,743...25,832,052
Ensembl chr 6:25,782,915...25,832,052
|
|
G |
SLC22A1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:160,121,815...160,158,718
Ensembl chr 6:160,121,815...160,158,718
|
|
G |
SLC51A |
solute carrier family 51 member A |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:196,216,534...196,233,427
Ensembl chr 3:196,211,487...196,243,178
|
|
G |
SLC51B |
SLC51 subunit beta |
multiple interactions |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA |
CTD |
PMID:32152650 |
|
NCBI chr15:65,045,387...65,053,397
Ensembl chr15:65,045,387...65,053,397
|
|
G |
SLCO1B1 |
solute carrier organic anion transporter family member 1B1 |
decreases expression multiple interactions |
EXP |
Atazanavir Sulfate results in decreased expression of SLCO1B1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLCO1B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLCO1B1 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr12:21,131,194...21,239,796
Ensembl chr12:21,131,194...21,239,796
|
|
G |
SOD2 |
superoxide dismutase 2 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA Atazanavir Sulfate results in increased expression of SOD2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 6:159,669,069...159,762,281
Ensembl chr 6:159,669,069...159,762,529
|
|
G |
SORL1 |
sortilin related receptor 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:121,452,314...121,633,763
Ensembl chr11:121,452,314...121,633,763
|
|
G |
SQSTM1 |
sequestosome 1 |
multiple interactions increases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA Atazanavir Sulfate results in increased expression of SQSTM1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:179,806,393...179,838,078
Ensembl chr 5:179,806,398...179,838,078
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
SRP72 |
signal recognition particle 72 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:56,467,617...56,503,681
Ensembl chr 4:56,467,617...56,503,681
|
|
G |
SULT2A1 |
sulfotransferase family 2A member 1 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA Atazanavir Sulfate results in decreased expression of SULT2A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:47,870,467...47,886,315
Ensembl chr19:47,870,467...47,886,315
|
|
G |
TFPI |
tissue factor pathway inhibitor |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:187,464,230...187,554,435
Ensembl chr 2:187,464,230...187,565,760
|
|
G |
TLR4 |
toll like receptor 4 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:117,704,403...117,724,735
Ensembl chr 9:117,704,175...117,724,735
|
|
G |
TNFRSF10A |
TNF receptor superfamily member 10a |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:23,190,452...23,225,102
Ensembl chr 8:23,190,452...23,225,102
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:172,505,508...172,523,430
Ensembl chr 3:172,505,508...172,523,475
|
|
G |
TNFSF11 |
TNF superfamily member 11 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:42,562,736...42,608,013
Ensembl chr13:42,562,736...42,608,013
|
|
G |
UGT2B15 |
UDP glucuronosyltransferase family 2 member B15 |
multiple interactions |
EXP |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of UGT2B15 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:68,646,597...68,670,652
Ensembl chr 4:68,646,597...68,670,652
|
|
G |
UGT2B4 |
UDP glucuronosyltransferase family 2 member B4 |
multiple interactions decreases expression |
EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT2B4 mRNA Atazanavir Sulfate results in decreased expression of UGT2B4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:69,480,165...69,526,014
Ensembl chr 4:69,480,165...69,526,014
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
cefoselis inhibits the reaction [SLC22A6 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:16098483 |
|
NCBI chr11:62,976,597...62,984,967
Ensembl chr11:62,936,385...62,984,967
|
|
G |
SLC22A8 |
solute carrier family 22 member 8 |
increases uptake multiple interactions |
EXP |
SLC22A8 protein results in increased uptake of cefoselis cefoselis inhibits the reaction [SLC22A8 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:16098483 |
|
NCBI chr11:62,992,824...63,015,841
Ensembl chr11:62,989,154...63,015,841
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCB1 mRNA; Erythromycin Estolate results in increased expression of ABCB1A mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 7:87,503,017...87,713,295
Ensembl chr 7:87,503,017...87,713,323
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases expression decreases activity |
ISO EXP |
Erythromycin Estolate results in decreased expression of ABCB11 mRNA Erythromycin Estolate results in decreased activity of ABCB11 protein |
CTD |
PMID:17522070 PMID:20829430 PMID:23956101 PMID:28437613 |
|
NCBI chr 2:168,915,390...169,031,324
Ensembl chr 2:168,915,498...169,031,324
|
|
G |
ABCC3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCC3 mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr17:50,634,881...50,692,253
Ensembl chr17:50,634,777...50,692,253
|
|
G |
ABCG5 |
ATP binding cassette subfamily G member 5 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCG5 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:43,806,211...43,839,231
Ensembl chr 2:43,812,472...43,838,865
|
|
G |
ABCG8 |
ATP binding cassette subfamily G member 8 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ABCG8 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:43,838,971...43,882,988
Ensembl chr 2:43,831,942...43,882,988
|
|
G |
ACADM |
acyl-CoA dehydrogenase medium chain |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:75,724,709...75,763,679
Ensembl chr 1:75,724,431...75,787,575
|
|
G |
ACLY |
ATP citrate lyase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACLY mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:41,866,917...41,930,545
Ensembl chr17:41,866,917...41,930,542
|
|
G |
ACSL1 |
acyl-CoA synthetase long chain family member 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ACSL1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:184,755,595...184,826,594
Ensembl chr 4:184,755,595...184,826,818
|
|
G |
ALDH1A1 |
aldehyde dehydrogenase 1 family member A1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 9:72,900,671...72,953,053
Ensembl chr 9:72,900,671...73,080,442
|
|
G |
ALDH3A2 |
aldehyde dehydrogenase 3 family member A2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ALDH3A2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:19,648,136...19,677,596
Ensembl chr17:19,648,136...19,685,760
|
|
G |
APEX1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of APEX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:20,455,226...20,457,767
Ensembl chr14:20,455,191...20,457,772
|
|
G |
ASPM |
assembly factor for spindle microtubules |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of ASPM mRNA Erythromycin Estolate results in increased expression of ASPM mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:197,084,127...197,146,669
Ensembl chr 1:197,084,121...197,146,694
|
|
G |
AURKB |
aurora kinase B |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of AURKB mRNA Erythromycin Estolate results in decreased expression of AURKB mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:8,204,731...8,210,575
Ensembl chr17:8,204,733...8,210,600
|
|
G |
BAX |
BCL2 associated X, apoptosis regulator |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of BAX mRNA |
CTD |
PMID:12883083 |
|
NCBI chr19:48,954,875...48,961,798
Ensembl chr19:48,954,815...48,961,798
|
|
G |
BCL2 |
BCL2 apoptosis regulator |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of BCL2 mRNA |
CTD |
PMID:12883083 |
|
NCBI chr18:63,123,346...63,320,090
Ensembl chr18:63,123,346...63,320,128
|
|
G |
BTG2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of BTG2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:203,305,519...203,309,602
Ensembl chr 1:203,305,491...203,309,602
|
|
G |
CA1 |
carbonic anhydrase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CAR1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:85,327,608...85,378,113
Ensembl chr 8:85,327,608...85,379,014
|
|
G |
CACNA1I |
calcium voltage-gated channel subunit alpha1 I |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CACNA1I mRNA |
CTD |
PMID:24412560 |
|
NCBI chr22:39,570,753...39,689,735
Ensembl chr22:39,570,753...39,689,735
|
|
G |
CALU |
calumenin |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CALU mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:128,739,359...128,773,400
Ensembl chr 7:128,739,292...128,773,400
|
|
G |
CAT |
catalase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CAT mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:34,438,934...34,472,060
Ensembl chr11:34,438,934...34,472,060
|
|
G |
CCN2 |
cellular communication network factor 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CCN2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:131,948,176...131,951,372
Ensembl chr 6:131,948,176...131,951,372
|
|
G |
CCNA2 |
cyclin A2 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CCNA2 mRNA Erythromycin Estolate results in decreased expression of CCNA2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:121,816,444...121,823,883
Ensembl chr 4:121,816,444...121,823,883
|
|
G |
CCNB1 |
cyclin B1 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of CCNB1 mRNA Erythromycin Estolate results in increased expression of CCNB1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:69,167,150...69,178,245
Ensembl chr 5:69,167,135...69,178,245
|
|
G |
CDCA3 |
cell division cycle associated 3 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of CDCA3 mRNA Erythromycin Estolate results in increased expression of CDCA3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:6,844,798...6,851,286
Ensembl chr12:6,844,793...6,851,292
|
|
G |
CDK1 |
cyclin dependent kinase 1 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CDK1 mRNA Erythromycin Estolate results in decreased expression of CDK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:60,778,331...60,794,852
Ensembl chr10:60,778,331...60,794,852
|
|
G |
CEACAM1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr19:42,507,306...42,528,481
Ensembl chr19:42,507,304...42,561,234
|
|
G |
CENPW |
centromere protein W |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of CENPW mRNA Erythromycin Estolate results in decreased expression of CENPW mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:126,340,115...126,483,320
Ensembl chr 6:126,340,115...126,348,875
|
|
G |
CES2 |
carboxylesterase 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CES2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr16:66,934,471...66,945,096
Ensembl chr16:66,934,444...66,945,096
|
|
G |
CHD2 |
chromodomain helicase DNA binding protein 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CHD2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:92,900,324...93,027,996
Ensembl chr15:92,886,203...93,027,996
|
|
G |
CTSL |
cathepsin L |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CTSL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 9:87,726,119...87,731,469
Ensembl chr 9:87,724,051...87,731,469
|
|
G |
CYB5R3 |
cytochrome b5 reductase 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr22:42,617,840...42,649,392
Ensembl chr22:42,615,730...42,720,870
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP1A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:74,719,542...74,725,528
Ensembl chr15:74,719,542...74,725,536
|
|
G |
CYP3A5 |
cytochrome P450 family 3 subfamily A member 5 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP3A9 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:99,648,194...99,679,996
Ensembl chr 7:99,648,194...99,679,996
|
|
G |
CYP8B1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of CYP8B1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:42,872,192...42,875,879
Ensembl chr 3:42,856,005...42,875,898
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of DDIT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:57,516,588...57,520,517
Ensembl chr12:57,516,588...57,521,737
|
|
G |
DUT |
deoxyuridine triphosphatase |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of DUT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:48,331,095...48,343,373
Ensembl chr15:48,331,011...48,343,373
|
|
G |
ECT2 |
epithelial cell transforming 2 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of ECT2 mRNA Erythromycin Estolate results in increased expression of ECT2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:172,750,726...172,829,265
Ensembl chr 3:172,750,682...172,821,474
|
|
G |
FABP1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FABP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:88,122,982...88,128,062
Ensembl chr 2:88,122,982...88,128,062
|
|
G |
FADS1 |
fatty acid desaturase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FADS1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:61,799,627...61,817,003
Ensembl chr11:61,799,627...61,829,318
|
|
G |
FAM111A |
FAM111 trypsin like peptidase A |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of FAM111A mRNA Erythromycin Estolate results in decreased expression of FAM111A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr11:59,142,856...59,155,039
Ensembl chr11:59,142,748...59,155,039
|
|
G |
FASN |
fatty acid synthase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FASN mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:82,078,338...82,098,236
Ensembl chr17:82,078,338...82,098,294
|
|
G |
FGA |
fibrinogen alpha chain |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:154,583,126...154,590,742
Ensembl chr 4:154,583,126...154,590,742
|
|
G |
FGB |
fibrinogen beta chain |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:154,562,980...154,572,807
Ensembl chr 4:154,563,011...154,572,807
|
|
G |
FMO1 |
flavin containing dimethylaniline monoxygenase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of FMO1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:171,248,494...171,285,978
Ensembl chr 1:171,248,471...171,285,978
|
|
G |
G6PC1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of G6PC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:42,900,799...42,914,438
Ensembl chr17:42,900,797...42,914,438
|
|
G |
GADD45A |
growth arrest and DNA damage inducible alpha |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of GADD45A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:67,685,201...67,688,334
Ensembl chr 1:67,685,201...67,688,334
|
|
G |
GCK |
glucokinase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GCK mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:44,143,213...44,189,439
Ensembl chr 7:44,143,213...44,198,170
|
|
G |
GPX1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GPX1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:49,357,176...49,358,353
Ensembl chr 3:49,357,174...49,358,605
|
|
G |
GPX2 |
glutathione peroxidase 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of GPX2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:64,939,158...64,942,745
Ensembl chr14:64,939,152...64,942,746
|
|
G |
GSTM3 |
glutathione S-transferase mu 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:109,733,937...109,741,038
Ensembl chr 1:109,733,932...109,741,038
|
|
G |
HIBADH |
3-hydroxyisobutyrate dehydrogenase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:27,525,442...27,662,883
Ensembl chr 7:27,525,442...27,662,883
|
|
G |
HMMR |
hyaluronan mediated motility receptor |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of HMMR mRNA Erythromycin Estolate results in decreased expression of HMMR mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:163,460,632...163,491,941
Ensembl chr 5:163,460,203...163,491,941
|
|
G |
IGF2R |
insulin like growth factor 2 receptor |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGF2R mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:159,969,082...160,111,504
Ensembl chr 6:159,969,082...160,113,507
|
|
G |
IGFBP1 |
insulin like growth factor binding protein 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGFBP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:45,888,488...45,893,660
Ensembl chr 7:45,888,360...45,893,660
|
|
G |
IGFBP2 |
insulin like growth factor binding protein 2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of IGFBP2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:216,632,828...216,664,436
Ensembl chr 2:216,632,828...216,664,436
|
|
G |
IP6K2 |
inositol hexakisphosphate kinase 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of IP6K2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:48,688,003...48,717,221
Ensembl chr 3:48,688,003...48,740,353
|
|
G |
ISY1 |
ISY1 splicing factor homolog |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ISY1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:129,127,415...129,161,063
Ensembl chr 3:129,127,415...129,161,063
|
|
G |
KIF20B |
kinesin family member 20B |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of KIF20B mRNA Erythromycin Estolate results in decreased expression of KIF20B mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:89,701,590...89,774,934
Ensembl chr10:89,701,590...89,774,939
|
|
G |
KIF23 |
kinesin family member 23 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of KIF23 mRNA Erythromycin Estolate results in decreased expression of KIF23 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:69,414,349...69,448,427
Ensembl chr15:69,414,246...69,448,427
|
|
G |
KIF2C |
kinesin family member 2C |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of KIF2C mRNA Erythromycin Estolate results in increased expression of KIF2C mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 1:44,739,837...44,767,767
Ensembl chr 1:44,739,818...44,767,767
|
|
G |
KRT18 |
keratin 18 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of KRT18 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:52,948,855...52,952,906
Ensembl chr12:52,948,871...52,952,906
|
|
G |
LBP |
lipopolysaccharide binding protein |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr20:38,346,482...38,377,013
Ensembl chr20:38,346,482...38,377,013
|
|
G |
LGALS3 |
galectin 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LGALS3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:55,129,252...55,145,430
Ensembl chr14:55,124,110...55,145,423
|
|
G |
LIPC |
lipase C, hepatic type |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr15:58,431,991...58,569,844
Ensembl chr15:58,410,569...58,569,844
|
|
G |
LPIN1 |
lipin 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of LPIN1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:11,677,544...11,827,409
Ensembl chr 2:11,677,595...11,827,409
|
|
G |
LPL |
lipoprotein lipase |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of LPL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:19,939,253...19,967,259
Ensembl chr 8:19,901,717...19,967,259
|
|
G |
MAOB |
monoamine oxidase B |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of MAOB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:43,766,610...43,882,450
Ensembl chr X:43,766,610...43,882,450
|
|
G |
MIR16-2 |
microRNA 16-2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of MIR16 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:160,404,745...160,404,825
Ensembl chr 3:160,404,745...160,404,825
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of MYC mRNA Erythromycin Estolate results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 PMID:24412560 |
|
NCBI chr 8:127,735,434...127,742,951
Ensembl chr 8:127,735,434...127,742,951
|
|
G |
NCAPH |
non-SMC condensin I complex subunit H |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of NCAPH mRNA Erythromycin Estolate results in increased expression of NCAPH mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:96,335,766...96,377,091
Ensembl chr 2:96,335,766...96,377,091
|
|
G |
NFKBIB |
NFKB inhibitor beta |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of NFKBIB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr19:38,899,666...38,908,889
Ensembl chr19:38,899,700...38,908,893
|
|
G |
NOCT |
nocturnin |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of NOCT mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:139,015,781...139,045,939
Ensembl chr 4:139,015,781...139,045,939
|
|
G |
NUSAP1 |
nucleolar and spindle associated protein 1 |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of NUSAP1 mRNA Erythromycin Estolate results in decreased expression of NUSAP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:41,332,881...41,381,046
Ensembl chr15:41,320,794...41,381,050
|
|
G |
OTC |
ornithine transcarbamylase |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:38,327,684...38,422,928
Ensembl chr X:38,327,598...38,422,908
|
|
G |
PCLAF |
PCNA clamp associated factor |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of PCLAF mRNA Erythromycin Estolate results in increased expression of PCLAF mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:64,364,304...64,387,687
Ensembl chr15:64,364,304...64,387,687
|
|
G |
PCMTD1 |
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PCMTD1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 8:51,817,575...51,899,186
Ensembl chr 8:51,817,575...51,899,186
|
|
G |
PDK4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PDK4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:95,583,499...95,596,516
Ensembl chr 7:95,583,499...95,596,516
|
|
G |
PER1 |
period circadian regulator 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PER1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr17:8,140,472...8,152,404
Ensembl chr17:8,140,467...8,156,506
|
|
G |
PFKFB3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PFKFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr10:6,144,921...6,326,637
Ensembl chr10:6,144,934...6,254,644
|
|
G |
PKLR |
pyruvate kinase L/R |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:155,289,293...155,308,654
Ensembl chr 1:155,289,293...155,301,438
|
|
G |
PYGL |
glycogen phosphorylase L |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of PYGL mRNA |
CTD |
PMID:17522070 |
|
NCBI chr14:50,905,217...50,944,483
Ensembl chr14:50,857,891...50,944,483
|
|
G |
RAD51 |
RAD51 recombinase |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of RAD51 mRNA Erythromycin Estolate results in decreased expression of RAD51 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr15:40,694,733...40,732,340
Ensembl chr15:40,694,774...40,732,340
|
|
G |
RRM2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of RRM2 mRNA Erythromycin Estolate results in increased expression of RRM2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:10,122,568...10,211,010
Ensembl chr 2:10,120,698...10,211,725
|
|
G |
S100A8 |
S100 calcium binding protein A8 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of S100A8 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:153,390,032...153,422,583
Ensembl chr 1:153,390,032...153,391,073
|
|
G |
S100A9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:153,357,854...153,361,023
Ensembl chr 1:153,357,854...153,361,023
|
|
G |
SERPINA7 |
serpin family A member 7 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SERPINA7 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:106,032,435...106,038,727
Ensembl chr X:106,032,435...106,038,727
|
|
G |
SERTAD3 |
SERTA domain containing 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SERTAD3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:40,440,844...40,444,335
Ensembl chr19:40,440,844...40,444,335
|
|
G |
SHCBP1 |
SHC binding and spindle associated 1 |
decreases expression increases expression |
ISO |
Erythromycin Estolate results in decreased expression of SHCBP1 mRNA Erythromycin Estolate results in increased expression of SHCBP1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr16:46,578,591...46,621,379
Ensembl chr16:46,578,591...46,621,379
|
|
G |
SLC38A2 |
solute carrier family 38 member 2 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SLC38A2 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:46,358,188...46,372,773
Ensembl chr12:46,358,188...46,372,773
|
|
G |
SLCO1A2 |
solute carrier organic anion transporter family member 1A2 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr12:21,264,600...21,419,634
Ensembl chr12:21,264,600...21,419,594
|
|
G |
SLCO1B3 |
solute carrier organic anion transporter family member 1B3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SLCO1B2 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:20,810,705...20,916,911
Ensembl chr12:20,810,702...20,916,911
|
|
G |
SPC25 |
SPC25 component of NDC80 kinetochore complex |
increases expression decreases expression |
ISO |
Erythromycin Estolate results in increased expression of SPC25 mRNA Erythromycin Estolate results in decreased expression of SPC25 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 2:168,861,521...168,890,430
Ensembl chr 2:168,834,132...168,913,371
|
|
G |
SPIN2B |
spindlin family member 2B |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SPIN2B mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:57,119,682...57,121,548
Ensembl chr X:57,118,551...57,121,548
|
|
G |
SPINK1 |
serine peptidase inhibitor Kazal type 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SPINK1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:147,824,582...147,839,196
Ensembl chr 5:147,824,572...147,831,671
|
|
G |
SREBF1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:17,811,334...17,836,986
Ensembl chr17:17,810,399...17,837,002
|
|
G |
STAT3 |
signal transducer and activator of transcription 3 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of STAT3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:42,313,324...42,388,442
Ensembl chr17:42,313,324...42,388,568
|
|
G |
STYXL1 |
serine/threonine/tyrosine interacting like 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of STYXL1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 7:75,996,337...76,048,000
Ensembl chr 7:75,996,338...76,048,004
|
|
G |
SUGT1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of SUGT1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr13:52,652,836...52,700,909
Ensembl chr13:52,652,709...52,700,909
|
|
G |
TGFB3 |
transforming growth factor beta 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TGFB3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr14:75,958,097...75,983,011
Ensembl chr14:75,958,097...75,983,011
|
|
G |
THRSP |
thyroid hormone responsive |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of THRSP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr11:78,063,861...78,068,351
Ensembl chr11:78,063,861...78,068,351
|
|
G |
TIMP1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:47,582,436...47,586,789
Ensembl chr X:47,582,408...47,586,789
|
|
G |
TMCC1 |
transmembrane and coiled-coil domain family 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TMCC1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 3:129,647,792...129,893,711
Ensembl chr 3:129,647,792...129,893,711
|
|
G |
TNFAIP3 |
TNF alpha induced protein 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TNFAIP3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 6:137,866,349...137,883,312
Ensembl chr 6:137,867,214...137,883,314
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:6,328,771...6,342,076
Ensembl chr12:6,328,757...6,342,114
|
|
G |
TP53 |
tumor protein p53 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr17:7,668,421...7,687,490
Ensembl chr17:7,661,779...7,687,546
|
|
G |
TSC22D3 |
TSC22 domain family member 3 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TSC22D3 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr X:107,713,221...107,775,988
Ensembl chr X:107,713,221...107,777,342
|
|
G |
TTR |
transthyretin |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TTR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr18:31,591,877...31,598,821
Ensembl chr18:31,557,009...31,598,833
|
|
G |
TXNRD1 |
thioredoxin reductase 1 |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of TXNRD1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr12:104,215,779...104,350,307
Ensembl chr12:104,215,779...104,350,307
|
|
G |
UGT2A1 |
UDP glucuronosyltransferase family 2 member A1 complex locus |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of UGT2A1 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 4:69,588,417...69,653,247
Ensembl chr 4:69,588,417...69,653,249
|
|
G |
ZC3H13 |
zinc finger CCCH-type containing 13 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ZC3H13 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr13:45,954,465...46,052,746
Ensembl chr13:45,954,465...46,052,759
|
|
G |
ZNF354A |
zinc finger protein 354A |
decreases expression |
ISO |
Erythromycin Estolate results in decreased expression of ZFP354A mRNA |
CTD |
PMID:24412560 |
|
NCBI chr 5:178,711,512...178,730,659
Ensembl chr 5:178,711,512...178,730,659
|
|
G |
ZNF574 |
zinc finger protein 574 |
increases expression |
ISO |
Erythromycin Estolate results in increased expression of ZFP574 mRNA |
CTD |
PMID:24412560 |
|
NCBI chr19:42,068,477...42,081,552
Ensembl chr19:42,068,477...42,081,552
|
|